Ga Syfovre denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits Syfovre Quantity — and How to Appeal

Syfovre (pegcetacoplan) is administered as an intravitreal injection, typically on a defined schedule per the FDA-approved prescribing information. Aetna's quantity-limit policy restricts coverage to a specific number of doses or injections per eye per time period. A quantity-limit denial means the volume or frequency requested exceeds what Aetna's policy authorizes — this can occur when a patient requires bilateral treatment, when the dosing interval differs from the policy's assumption, or when an annual reset has not been applied correctly.

## Why This Denial Is Appealable

Quantity limits are set administratively and may not account for bilateral GA, the patient's specific disease burden, or the FDA-approved dosing schedule in the prescribing information. If the requested quantity matches the FDA-approved dosing regimen and the patient has bilateral disease, the denial is likely based on a policy that assumed unilateral treatment. Your prescriber's documentation of the clinical rationale is the key to reversal.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: You are entitled to a full-and-fair internal review and to receive the specific quantity-limit policy that was applied.
• External Review: If the internal appeal is denied, an Independent Review Organization (IRO) can review whether the quantity limit as applied is clinically appropriate. The standard external review window is approximately four months from the final internal denial. Expedited review is available when delay would seriously jeopardize vision or health.

## Appeal Timeline

1. Obtain the denial letter and identify the specific limit applied (per eye, per period, bilateral vs. unilateral). 2. Confirm whether the requested quantity aligns with the FDA-approved dosing schedule. 3. Submit the internal appeal with prescriber documentation and FDA label support. 4. Escalate to external review if the internal appeal is upheld.

## Documentation to Gather

• FDA prescribing information: The current Syfovre label showing the approved dosing schedule and frequency for intravitreal administration.
• Bilateral disease documentation: If both eyes are affected, retinal imaging for each eye confirming GA in both, with separate documentation of each eye's disease characteristics.
• Prescriber medical-necessity letter: Your retina specialist should specify the number of doses requested, which eye(s) are being treated, the clinical rationale for the requested quantity, and confirm alignment with the FDA-approved dosing regimen.
• Clinical severity documentation: Chart notes supporting the frequency and duration of treatment as medically necessary given the rate of GA progression and visual function status.

## Criteria-Mapping Strategy

Obtain the current Aetna Clinical Policy Bulletin and any quantity-limit addendum for Syfovre. Identify whether the limit was applied per eye or across both eyes. If the patient has bilateral GA and the limit reflects a unilateral assumption, state that explicitly and provide bilateral imaging to support a quantity consistent with bilateral treatment. Map the requested quantity to the FDA-approved dosing schedule, showing they are consistent. If the treating retina specialist's dosing plan differs from the most common interval, include a clinical note explaining the individualized rationale and its consistency with the prescribing information and applicable professional society guidance.